OncoMatch/Clinical Trials/NCT06114511
A Study of BL-M07D1 in Patients With HER2-mutated, Locally Advanced or Metastatic Non-small-cell Lung Cancer
Is NCT06114511 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1/2 trial studies BL-M07D1 for non-small cell lung cancer.
Treatment: BL-M07D1 — This phase Ib/II study is designed to evaluate the safety, tolerability, pharmacokinetics, and efficacy of injectable BL-M07D1 in patients with HER2-mutated, locally advanced or metastatic non-small cell lung cancer.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Non-Small Cell Lung Carcinoma
Biomarker criteria
Required: HER2 (ERBB2) sensitive mutation
Confirmed known HER2-sensitive mutations
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Must have received: platinum-based chemotherapy — advanced/metastatic
Patients in the advanced stage who had received platinum-based chemotherapy and immunotherapy concurrent or sequential therapy were unable to tolerate standard treatment or had disease progression during or after treatment
Must have received: immunotherapy — advanced/metastatic
Patients in the advanced stage who had received platinum-based chemotherapy and immunotherapy concurrent or sequential therapy were unable to tolerate standard treatment or had disease progression during or after treatment
Cannot have received: antibody-drug conjugate containing a camptothecin derivative (topoisomerase I inhibitor)
Prior treatment with an ADC drug containing a camptothecin derivative (topoisomerase I inhibitor) as a toxin
Lab requirements
Blood counts
Kidney function
Liver function
Cardiac function
no severe cardiac dysfunction, left ventricular ejection fraction ≥50%
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06114511 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior antibody-drug conjugate containing a camptothecin derivative (topoisomerase I inhibitor) disqualifies patients from enrollment.
Does this trial require ERBB2?
Yes, ERBB2 sensitive mutation is a required biomarker for enrollment.
Is there an age limit?
Yes. Patients must be 75 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify